FDA Approval for UKONIQ

2/5/21 1:35:26 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

New Drug Application (NDA): 213176
Company: TG THERAPEUTICS INC

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
UKONIQ	UMBRALISIB	200MG	TABLET;ORAL	Prescription	None	TBD	No

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
02/05/2021	ORIG-2	Approval	Type 1 - New Molecular Entity	PRIORITY		Label is not available on this site.
02/05/2021	ORIG-1	Approval	Type 1 - New Molecular Entity	PRIORITY		Label is not available on this site.

Recent Analyst Ratings for

Date	Price Target	Rating	Analyst
10/29/2024	$50.00	Buy	TD Cowen
8/2/2023	$16.00 → $12.00	Sell → Neutral	Goldman
6/26/2023	$55.00 → $40.00	Buy	Jefferies
5/20/2022	$5.00	Underperform	BofA Securities
2/23/2022	$49.00 → $35.00	Buy	B. Riley Securities
1/28/2022	$70.00 → $68.00	Buy	HC Wainwright & Co.
1/24/2022	$75.00 → $70.00	Buy	HC Wainwright & Co.
12/1/2021	$55.00 → $36.00	Outperform	Evercore ISI Group

More analyst ratings

Recent Analyst Ratings for $TGTX